Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235833 | 0.87 | MCL1 (0.47) | KDRMAP3K8NCOA3POLBPSMD14 | |
| SCHEMBL8346183 | 0.86 | SLC9A1 (0.41) | KDRMAP3K8NCOA3POLBPSMD14 | |
| Hydrochloric Acid SCHEMBL4244322 | 0.85 | KDR (0.41) | KDRMAP3K8NCOA3POLBPSMD14 | |
| SCHEMBL4236193 | 0.84 | KDR (0.39) | KDRMAP3K8POLBNR4A2MEN1 | |
| SCHEMBL4238309 | 0.83 | NR4A2 (0.60) | KDRNR4A2MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL4236283 | 0.83 | KDR (0.39) | KDRPOLBNR4A2MEN1NPC1 | |
| SCHEMBL28574684 | 0.77 | ALDH1A1 (0.57) | MAP3K8NCOA3POLBPSMD14TP53 | |
| SCHEMBL6818446 | 0.76 | HTR3A (0.49) | SCN9ACA12CA1CA2CA9 | |
| SCHEMBL6353133 | 0.74 | NCOA3 (0.48) | KDRMAP3K8NCOA3POLBPSMD14 | |
| SCHEMBL28581807 | 0.74 | HTR7 (0.41) | KDRMAP3K8NCOA3POLBPSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150025240-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-01-22 | — | — | US | disclosed |
| US-8871771-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-7745625-B2 | Prodrugs of piperazine and substituted piperidine antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| CN-1953985-B | Prodrugs of piperazine and substituted piperidine antiviral drugs | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-29 | — | — | US | disclosed |
| EP-1725569-B1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-1953985-A | Prodrugs of piperazine and substituted piperidine antiviral drugs | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1751161-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1906199-A | Diazaindole-dicarbonyl-piperazinyl antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2005-09-22 | — | — | US | disclosed |
| WO-2005054247-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | SCN9A 2115/4885KDR 4536/4885MAP3K8 3765/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | SCN9A 3931/4885KDR 2259/4885MAP3K8 4260/4885 |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | ZC3HAV1L, CCR5, CCRL2 | SCN9A 2633/4885KDR 4335/4885MAP3K8 4180/4885 |
| US-20150025240-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | SCN9A 1830/4885KDR 4273/4885MAP3K8 3609/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | SCN9A 2240/4885KDR 4405/4885MAP3K8 3775/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | SCN9A 4304/4885KDR 4317/4885MAP3K8 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.